Recently, Elisei et al. demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow-up. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.